Thomas V Ho

6544553, Apr 8, 2003

Dec 28, 1999

09/473548

David Chung Hsia - Irvine CA
Thomas Chun Ho - Irvine CA
Domingo Yap Tan - Irvine CA
Fredric B. Weihmuller - Huntington Beach CA

Watson Pharmaceuticals, Inc. - Corona CA

A61K 920

424465, 424451, 424452, 424457, 424458, 424464, 424468, 424469, 424470, 424489

Provided is an oral dosage form suitable to deliver a combined dosage of progesterone and which upon delivery through the gastrointestinal tract provides a blood concentration of from about 0. 1 ng/ml to about 400 ng/ml progesterone; said dosage form comprising a combination that includes (a) a first solid form comprising from about 25 mg to about 500 mg micronized progesterone in a solid polyethylene glycol carrier having an average molecular weight of from about 1000 to 10,000 and constituting at least about 30% of said first solid form; and (b) a second solid form comprising an estrogen.

6630166, Oct 7, 2003

Feb 12, 2002

10/076046

Thomas Ho - Irvine CA

Watson Pharmaceuticals, Inc. - Corona CA

A61K 936

424479, 424474, 424475, 424482

Oral conjugated estrogen formulations are disclosed and described. In one aspect, the oral formulation may be a tablet having a core and one or more coatings thereon. In addition to conjugated estrogen ingredients, the core may include one or more organic excipients and one or more inorganic excipients. In one aspect, the organic excipients may include less than about 20% w/w of a cellulose ingredient, and less than about 50% w/w of a sugar ingredient. In another aspect, the inorganic excipients may include less than about 10% w/w of a calcium phosphate tribasic ingredient. In yet another aspect, the formulation does not crack when stored at about 40 Â C. and about 75% relative humidity for about 2 months.

6866865, Mar 15, 2005

Feb 24, 2003

10/370746

David Chung Hsia - Irvine CA, US
Thomas Chun Ho - Irvine CA, US
Domingo Yap Tan - Irvine CA, US
Fredric B. Weihmuller - Huntington Beach CA, US

Watson Pharmaceuticals, Inc. - Corona CA

A61K009/14
A61K009/20

424465, 424464, 424467, 424489

Oral progesterone unit dosage forms comprising micronized progesterone and a solid polymeric carrier are provided. The dosage forms, upon oral administration, provide a therapeutically effective blood level of progesterone to a subject. The therapeutically effective blood level of progesterone may range from about 0. 1 ng/ml to about 400 ng/ml. The dosage forms can be prepared for immediate as well as sustained release. The oral progesterone dosage form can be combined with an estrogen dosage form to provide combination hormone therapy.

7303763, Dec 4, 2007

Sep 22, 2003

10/668104

Thomas Ho - Irvine CA, US

Watson Laboratories, Inc. - Salt Lake City UT

A61K 9/36
A61K 9/28
A61K 9/30
A61K 9/32

424479, 424474, 424475, 424482

Oral conjugated estrogen formulations are disclosed and described. In one aspect, the oral formulation may be a tablet having a core and one or more coatings thereon. In addition to conjugated estrogen ingredients, the core may include one or more organic excipients and one or more inorganic excipients. In one aspect, the organic excipients may include less than about 20% w/w of a cellulose ingredient, and less than about 50% w/w of a sugar ingredient. In another aspect, the inorganic excipients may include less than about 10% w/w of a calcium phosphate tribasic ingredient. In yet another aspect, the formulation does not crack when stored at about 40 C. and about 75% relative humidity for about 2 months.